Vincerx Pharma Investor Relations Material

Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company engaged in the development of therapies designed to address unmet medical needs in cancer treatment. Their research focuses on creating new treatment options through the development of drugs like enitociclib, a cyclin-dependent kinase-9 inhibitor currently in clinical trials for patients with hematologic malignancies. Another key area of their research involves VIP236, a small molecule drug conjugate, also in trials, targeting solid tumors. Additionally, Vincerx Pharma is exploring product candidates such as VIP943 and VIP924 for treating hematologic malignancies. The company is headquartered in Palo Alto, California, and its shares are listed on the Nasdaq.